Last reviewed · How we verify
NCT06604910
Branched Chained Amino Acid Supplement in Patients Undergoing Lower Limb Bone Cancer Curettage for Bone Metastasis
NA trial testing branched chained amino acid in Muscle Loss in 40 participants. Not yet recruiting.
31 December 2029
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 25 September 2024 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2030 |
Drugs / interventions tested
- branched chained amino acid
Conditions studied
- Muscle Loss — all drugs for Muscle Loss →
Sponsor
National Taiwan University Hospital
Who can join
Adults 20 to 80, any sex, with Muscle Loss. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Postoperative muscle loss is common in patients with bone metastases undergoing lower limb bone cancer curettage, affecting both limb skeletal muscles and potentially swallowing-related muscles. Rectus femoris thickness, measured via ultrasound on postoperative day seven, is used to assess this loss. Branched-chain amino acids (BCAAs) are important for muscle protein synthesis, but little research exists on whether postoperative oral BCAA supplementation can reduce muscle loss, swallowing function deterioration, and short-term complications. This study investigates if BCAA supplementation from postoperative day one to day 30 can reduce muscle loss (primary endpoint: rectus femoris thickness on day seven) and mitigate swallowing function decline, pharyngeal muscle contraction loss, and complications within three months post-surgery.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Metabolic Adaptations in Cancer Progression: Optimization Strategies and Therapeutic Targets.
Dominiak A, Chełstowska B, Nowicka G. · · 2025 · cited 5× · PMID 40723225 · DOI 10.3390/cancers17142341
Verify or expand the search:
- PubMed search for NCT06604910
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Muscle Loss
Currently open trials in the same condition.
- NCT06728722 — Ultrasound Detection of Body Composition in Critical Care · recruiting
- NCT06458530 — Examining the Effects of Vivo on Physical Function and Glycemic Level in Sedentary Older With Prediabetes. · NA · active not recruiting
- NCT06411964 — Galactooligosaccharide and Aging · NA · recruiting
- NCT06488872 — Comparison of Computed Tomography Data With Routine Measurements Concerning Bone and Muscle Health of Aged Individuals · recruiting
- NCT06136221 — Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease · NA · recruiting
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06604910 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 20 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06604910.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing